Impact of censoring data below an arbitrary quantification limit on structural model misspecification.
about
A Bayesian approach for PK/PD modeling with PD data below limit of quantification.Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification.Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data.Handling data below the limit of quantification in mixed effect models.Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.Tips and traps analyzing pediatric PK data.Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study designUse of pharmacokinetic data below lower limit of quantitation valuesPopulation pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsMorbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patientsPopulation pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaPopulation-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations.Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation.Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance.Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
P2860
Q30573792-5AC4F44D-5970-4A67-9059-9CF78F277959Q30964404-E0E2CA51-1228-4B15-A25A-CF21A408626FQ31118795-FC16EF72-72BF-4DF3-9CF0-D83AA9E57A2FQ31152727-B9657746-E3C3-4DFF-9CD2-E048FC68604BQ33447430-218CEB3A-8270-4B73-8946-C0CA667F5E74Q33521471-9F1E7281-29C2-4379-A49D-9EEBCAB40534Q33820152-DE95F182-C224-4511-863A-381D9A079D22Q33822458-8497B735-B7DF-42FB-A3DD-5B27EF19B8FBQ33917058-A92FEE96-C371-4975-AC98-DDD99ED77041Q34223916-38294B49-2EBD-4BB0-BD19-62EEA5C64DA7Q34315916-36C8BBE0-0DBD-489B-9B0D-76B75340AB00Q35126138-04F2A073-7412-4EA3-948E-EE0A020EDAAAQ36243689-2CB5B864-EEB9-489D-8FA5-85D0B7E24D12Q37026910-27FB4AFB-42DE-49A5-9A05-5DAB8BCF0A69Q37030730-3023A470-E994-41D0-BE52-2724255FAC71Q37253554-7A580703-44E3-4C99-91E0-689DB5A9907DQ38844529-FF6790D4-D814-4712-BA55-7C0744AFF347Q38962938-943FB2A7-D78F-430B-BD82-D474BCDDB7E0Q38993405-F7D1C407-C53C-4BF3-82E1-910B19464AB9Q39175455-14C1EF90-F762-4739-AEFD-2126129B2FBEQ39538576-35FA96F9-4E16-425D-B8BB-31C966D6EED8Q39926646-8169449F-0D45-4B38-B960-0859CBE53836Q40075207-6A692A23-D04C-4596-8503-DE518925C29EQ41986943-7FF78B82-294B-4F09-B8CE-9487E8C5A16EQ43070221-40EEC942-694C-4A9C-994C-5D65C10B3A4FQ43687976-84546942-0A60-441C-9301-416E89222577Q44108202-739B7955-1B0A-4518-9744-C497E68584EFQ55331865-C813F086-D5D8-4559-825E-D4FBCDAB6E20
P2860
Impact of censoring data below an arbitrary quantification limit on structural model misspecification.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Impact of censoring data below ...... ctural model misspecification.
@ast
Impact of censoring data below ...... ctural model misspecification.
@en
type
label
Impact of censoring data below ...... ctural model misspecification.
@ast
Impact of censoring data below ...... ctural model misspecification.
@en
prefLabel
Impact of censoring data below ...... ctural model misspecification.
@ast
Impact of censoring data below ...... ctural model misspecification.
@en
P2093
P1476
Impact of censoring data below ...... ctural model misspecification.
@en
P2093
Courtney V Fletcher
Richard C Brundage
Wonkyung Byon
P2888
P304
P356
10.1007/S10928-007-9078-9
P577
2007-10-26T00:00:00Z
P6179
1023091556